News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Merck & Co., Inc. Unit Held Liable in Australian Vioxx Case
March 5, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Merck & Co's (MRK.N) one-time blockbuster arthritis drug Vioxx doubled the risk of heart attacks and was not fit for sale, an Australian court said on Friday, in a ruling against the U.S. group's Australian unit.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Asia
Australia
Merck & Co.
MORE ON THIS TOPIC
Immunology and inflammation
AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical
July 8, 2026
·
2 min read
·
Tristan Manalac
Obesity
Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending
July 7, 2026
·
4 min read
·
Gabrielle Masson
Editorial
Biotech’s China problem: An issue of national security or economic value for the US?
July 2, 2026
·
6 min read
·
Jef Akst
China
AstraZeneca taps China’s CSPC again, betting up to $1.77B to target kidney diseases
July 2, 2026
·
2 min read
·
Tristan Manalac